Melatonin, an Antitumor Necrosis Factor Therapy

Overview

Journal J Pineal Res

Publisher Wiley

Specialty Endocrinology

Date 2024 Dec 31

PMID 39740227

Authors

Ana Isabel Alvarez-Lopez

Ivan Cruz-Chamorro

Patricia Judith Lardone

Ignacio Bejarano

Karla Aspiazu-Hinostroza

Eduardo Ponce-Espana

Guillermo Santos-Sanchez

Nuria Alvarez-Sanchez

Antonio Carrillo-Vico

Affiliations

Soon will be listed here.

Abstract

Tumor necrosis factor (TNF) is a biomarker of inflammation whose levels are elevated in patients with several diseases associated with dysregulation of the immune response. The main limitations of currently used anti-TNF therapies are the induction of immunodepression, which in many cases leads to serious adverse effects such as infection and cancer, and the inability to cross the blood-brain barrier in neuroinflammatory conditions. Melatonin, in addition to being a chronobiotic compound, is widely known for its antioxidant and immunomodulatory capacity to control inflammatory processes in different pathological contexts. The aim of the present review is to address human-based studies that describe the effect of melatonin on TNF production. The review includes all the articles published in PubMed databases until April 15, 2024. After depuration, 45 studies were finally included in the review, 23 related to the in vitro action of melatonin in human cells and 22 in vivo studies in humans. Most of the data reviewed support the idea that melatonin has an immunosuppressive effect on TNF levels, which, together with its low toxicity profile, low cost, and ability to cross the blood-brain barrier, points to melatonin as a potential anti-TNF therapy. Therefore, improving our knowledge of the action of melatonin in regulating TNF through appropriate clinical trials would reveal the true potential of this molecule as a possible anti-TNF therapy.

Citing Articles

Melatonin from Plants: Going Beyond Traditional Central Nervous System Targeting-A Comprehensive Review of Its Unusual Health Benefits.

Fornari Laurindo L, Simili O, Cressoni Araujo A, Landgraf Guiguer E, Direito R, Valenti V Biology (Basel). 2025; 14(2).

PMID: 40001911 PMC: 11851571. DOI: 10.3390/biology14020143.

References

Chuang J, Mohan N, Meltz M, Reiter R . Effect of melatonin on NF-kappa-B DNA-binding activity in the rat spleen. Cell Biol Int. 1996; 20(10):687-92. DOI: 10.1006/cbir.1996.0091. View

Esmaeili Gouvarchin Ghaleh H, Hosseini A, Aghamollaei H, Fasihi-Ramandi M, Alishiri G, Saeedi-Boroujeni A . NLRP3 inflammasome activation and oxidative stress status in the mild and moderate SARS-CoV-2 infected patients: impact of melatonin as a medicinal supplement. Z Naturforsch C J Biosci. 2021; 77(1-2):37-42. DOI: 10.1515/znc-2021-0101. View

McCoy M, Tansey M . TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation. 2008; 5:45. PMC: 2577641. DOI: 10.1186/1742-2094-5-45. View

Yi Y, Tang H, Pi P, Zhang H, Du S, Ge W . Melatonin in cancer biology: pathways, derivatives, and the promise of targeted delivery. Drug Metab Rev. 2024; 56(1):62-79. DOI: 10.1080/03602532.2024.2305764. View

Chahbouni M, Lopez M, Molina-Carballo A, Haro T, Munoz-Hoyos A, Fernandez-Ortiz M . Melatonin Treatment Reduces Oxidative Damage and Normalizes Plasma Pro-Inflammatory Cytokines in Patients Suffering from Charcot-Marie-Tooth Neuropathy: A Pilot Study in Three Children. Molecules. 2017; 22(10). PMC: 6151441. DOI: 10.3390/molecules22101728. View

Carrillo-Vico A, Lardone P, Fernandez-Santos J, Martin-Lacave I, Calvo J, Karasek M . Human lymphocyte-synthesized melatonin is involved in the regulation of the interleukin-2/interleukin-2 receptor system. J Clin Endocrinol Metab. 2004; 90(2):992-1000. DOI: 10.1210/jc.2004-1429. View

Shafiei E, Bahtoei M, Raj P, Ostovar A, Iranpour D, Akbarzadeh S . Effects of N-acetyl cysteine and melatonin on early reperfusion injury in patients undergoing coronary artery bypass grafting: A randomized, open-labeled, placebo-controlled trial. Medicine (Baltimore). 2018; 97(30):e11383. PMC: 6078764. DOI: 10.1097/MD.0000000000011383. View

Thimmulappa R, Lee H, Rangasamy T, Reddy S, Yamamoto M, Kensler T . Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest. 2006; 116(4):984-95. PMC: 1421348. DOI: 10.1172/JCI25790. View

Babu G, Kumar A, Chandra R, Puri S, Kalita J, Misra U . Elevated inflammatory markers in a group of amyotrophic lateral sclerosis patients from northern India. Neurochem Res. 2008; 33(6):1145-9. DOI: 10.1007/s11064-007-9564-x. View

10.

Mesri Alamdari N, Mahdavi R, Roshanravan N, Lotfi Yaghin N, Ostadrahimi A, Faramarzi E . A double-blind, placebo-controlled trial related to the effects of melatonin on oxidative stress and inflammatory parameters of obese women. Horm Metab Res. 2014; 47(7):504-8. DOI: 10.1055/s-0034-1384587. View

11.

Gitto E, Reiter R, Amodio A, Romeo C, Cuzzocrea E, Sabatino G . Early indicators of chronic lung disease in preterm infants with respiratory distress syndrome and their inhibition by melatonin. J Pineal Res. 2004; 36(4):250-5. DOI: 10.1111/j.1600-079X.2004.00124.x. View

12.

Esposito E, Genovese T, Caminiti R, Bramanti P, Meli R, Cuzzocrea S . Melatonin reduces stress-activated/mitogen-activated protein kinases in spinal cord injury. J Pineal Res. 2008; 46(1):79-86. DOI: 10.1111/j.1600-079X.2008.00633.x. View

13.

Silva S, Rodrigues M, Ximenes V, Bueno-Da-Silva A, Amarante-Mendes G, Campa A . Neutrophils as a specific target for melatonin and kynuramines: effects on cytokine release. J Neuroimmunol. 2004; 156(1-2):146-52. DOI: 10.1016/j.jneuroim.2004.07.015. View

14.

Cai L, Chen Q, Yao Z, Sun Q, Wu L, Ni Y . Glucocorticoid receptors involved in melatonin inhibiting cell apoptosis and NLRP3 inflammasome activation caused by bacterial toxin pyocyanin in colon. Free Radic Biol Med. 2020; 162:478-489. DOI: 10.1016/j.freeradbiomed.2020.11.003. View

15.

Chahbouni M, Escames G, Venegas C, Sevilla B, Garcia J, Lopez L . Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy. J Pineal Res. 2010; 48(3):282-289. DOI: 10.1111/j.1600-079X.2010.00752.x. View

16.

Sagrillo-Fagundes L, Assuncao Salustiano E, Ruano R, Markus R, Vaillancourt C . Melatonin modulates autophagy and inflammation protecting human placental trophoblast from hypoxia/reoxygenation. J Pineal Res. 2018; 65(4):e12520. DOI: 10.1111/jpi.12520. View

17.

Uz T, Arslan A, Kurtuncu M, Imbesi M, Akhisaroglu M, Dwivedi Y . The regional and cellular expression profile of the melatonin receptor MT1 in the central dopaminergic system. Brain Res Mol Brain Res. 2005; 136(1-2):45-53. DOI: 10.1016/j.molbrainres.2005.01.002. View

18.

Merras-Salmio L, Kolho K . Golimumab Therapy in Six Patients With Severe Pediatric Onset Crohn Disease. J Pediatr Gastroenterol Nutr. 2016; 63(3):344-7. DOI: 10.1097/MPG.0000000000001165. View

19.

Heilig B, Fiehn C, Brockhaus M, Gallati H, Pezzutto A, Hunstein W . Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue disease. J Clin Immunol. 1993; 13(5):321-8. DOI: 10.1007/BF00920240. View

20.

Maxwell L, Zochling J, Boonen A, Singh J, Veras M, Tanjong Ghogomu E . TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015; (4):CD005468. PMC: 11200207. DOI: 10.1002/14651858.CD005468.pub2. View